A P/B of 2.21x sits below MS and JPM at roughly 2.6x but well above BAC and C, which suggests investors are treating GS as a premium franchise despite a return profile that has lagged peers. Forward P/E of 12.21x against trailing 16.93x indicates expected earnings normalization, which warrants monitoring because the trailing figure is depressed by volatile provisioning. The gap between price and recent ROE should be read as a bet on sustained fee and trading strength rather than as evidence of current value.

DuPont decomposition shows that with NIM near 0.2%, the bulk of revenue comes from fees, so ROE is driven by non-interest income and leverage rather than asset utilization. The fee share swung from negative in 2026Q1 to near 90% in 2024Q4, which suggests earnings quality is sensitive to trading and advisory cycles. Investors should monitor whether fee strength persists, as the ROE trajectory from 2.5% to 4.5% appears tied to these volatile revenue lines.

A NIM of roughly 0.2% is structurally thin, which is consistent with a model where lending is not the primary earnings engine, so efficiency matters more than spread. The drop in efficiency ratio to 60.5% suggests revenue grew faster than non-interest expense in the latest quarter, though a single quarter may not establish a durable trend. This appears to be a more meaningful driver of profitability than margin, and warrants further investigation into expense run-rate.

The compression of equity relative to assets, with equity rising only from $118.5B to $125.0B against substantial asset growth, suggests the balance sheet is expanding on a thinner base. Regulatory capital ratios such as CET1 are not included in the supplied data, so binding constraints cannot be confirmed directly. Investors should monitor capital return capacity against this leverage trend, as it may limit flexibility.